Brokerages expect that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will announce earnings of ($0.63) per share for the current quarter, Zacks reports. Three analysts have made estimates for Karyopharm Therapeutics’ earnings, with estimates ranging from ($0.69) to ($0.56). Karyopharm Therapeutics posted earnings of ($0.84) per share during the same quarter last year, which indicates a positive year over year growth rate of 25%. The firm is expected to issue its next quarterly earnings results on Thursday, August 3rd.

On average, analysts expect that Karyopharm Therapeutics will report full year earnings of ($2.61) per share for the current financial year, with EPS estimates ranging from ($2.81) to ($2.39). For the next year, analysts forecast that the firm will report earnings of ($2.41) per share, with EPS estimates ranging from ($2.90) to ($1.81). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Karyopharm Therapeutics.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, May 4th. The company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.04. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.02 million. During the same period last year, the firm earned ($0.75) earnings per share.

Several research firms have commented on KPTI. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price target on shares of Karyopharm Therapeutics in a report on Monday, May 15th. Jefferies Group LLC reiterated a “buy” rating and set a $14.00 price target on shares of Karyopharm Therapeutics in a report on Friday, March 3rd. Wedbush reiterated an “outperform” rating and set a $14.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, April 5th. Robert W. Baird reiterated an “outperform” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a report on Thursday, April 6th. Finally, Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Karyopharm Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $14.46.

Karyopharm Therapeutics (KPTI) traded down 0.22% during midday trading on Tuesday, reaching $9.18. 147,103 shares of the company were exchanged. The firm has a 50-day moving average price of $9.44 and a 200-day moving average price of $10.20. The company’s market capitalization is $432.54 million. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at about $343,000. State Street Corp boosted its position in shares of Karyopharm Therapeutics by 6.6% in the fourth quarter. State Street Corp now owns 406,103 shares of the company’s stock valued at $3,820,000 after buying an additional 25,015 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Karyopharm Therapeutics by 347.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 261,055 shares of the company’s stock valued at $2,454,000 after buying an additional 202,714 shares during the last quarter. Trexquant Investment LP bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at about $273,000. Finally, Metropolitan Life Insurance Co. NY boosted its position in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock valued at $206,000 after buying an additional 2,460 shares during the last quarter. Institutional investors and hedge funds own 56.97% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “-$0.63 Earnings Per Share Expected for Karyopharm Therapeutics Inc (KPTI) This Quarter” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/06/16/0-63-earnings-per-share-expected-for-karyopharm-therapeutics-inc-kpti-this-quarter-updated.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related stocks with our FREE daily email newsletter.